Edgar Filing: MEDICINES CO /DE - Form 4

MEDICINES Form 4	S CO /DE										
November 27	7, 2013										
							OMB APPROVAL				
CURIVI 4 UNITED STATES SECURITIES AND EXCHANGE COMM Washington, D.C. 20549					OMMISSION	OMB Number:	3235-0287				
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). TATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940						Expires:January 31, 2005Estimated average burden hours per response0.5					
(Print or Type F	Responses)										
1. Name and Address of Reporting Person <u>*</u> Shigeta Hiroaki			2. Issuer Name and Ticker or Trading Symbol MEDICINES CO /DE [MDCO]					5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Check				k all applicable)				
8 SYLVAN WAY			(Month/Day/Year) 11/25/2013					X_ Director10% Owner Officer (give titleOther (specify below)			
PARSIPPA	4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
		(7:n)									
(City)	(State)	(Zip)	Tabl	le I - Non-I	Derivative S	Securi	ties Acq	uired, Disposed of	, or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	ity(Month/Day/Year)Execution Date, if3)any		3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A)				Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	or (D)	Price	(Instr. 3 and 4)			
Common Stock	11/25/2013			М	17,039		\$ 21.14	39,388	D		
Common Stock (1)	11/25/2013			S	17,039	D	\$ 37.19 (2)	22,349	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: MEDICINES CO /DE - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour Underlying Securit (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amo or Num of Sh
Option (Right-to-buy)	\$ 21.14	11/25/2013		М	17,039	(3)	05/22/2023	Common Stock	17,0

Reporting Owners

Reporting Owner Name / Address		Relationsh				
	Director	10% Owner	Officer	ïcer Other		
Shigeta Hiroaki 8 SYLVAN WAY PARSIPPANY, NJ 07054	Х					
Signatures						
/s/ Paul Antinori, as Attorney-i Shigeta	r Mr.	11/27/2013				
**Signature of Reporting I		Date				
Evalenation of De						

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The common stock sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 program adopted by Mr. Shigeta on October 25, 2013.

The range of prices for the transactions reported on this line is between \$36.59 and \$37.72 per share. The price reported above reflects the(2) weighted average sales price. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full informaton regarding the number of shares sold at each separate price.

(3) As of November 25, 2013, the original grant (17,039 shares granted on May 22, 2012) was fully vested and exercised.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.